. 2015 Apr; 37(4):764-82.
doi: 10.1016/j.clinthera.2015.02.018.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

Kathleen M Mahoney 1 Gordon J Freeman 2 David F McDermott 3 
  • PMID: 25823918
  •     75 References
  •     215 citations


Purpose: Blocking the interaction between the programmed cell death (PD)-1 protein and one of its ligands, PD-L1, has been reported to have impressive antitumor responses. Therapeutics targeting this pathway are currently in clinical trials. Pembrolizumab and nivolumab are the first of this anti-PD-1 pathway family of checkpoint inhibitors to gain accelerated approval from the US Food and Drug Administration (FDA) for the treatment of ipilimumab-refractory melanoma. Nivolumab has been associated with improved overall survival compared with dacarbazine in patients with previously untreated wild-type serine/threonine-protein kinase B-raf proto-oncogene BRAF melanoma. Although the most mature data are in the treatment of melanoma, the FDA has granted approval of nivolumab for squamous cell lung cancer and the breakthrough therapy designation to immune- checkpoint inhibitors for use in other cancers: nivolumab, an anti-PD-1 monoclonal antibody, for Hodgkin lymphoma, and MPDL-3280A, an anti-PD-L1 monoclonal antibody, for bladder cancer and non-small cell lung cancer. Here we review the literature on PD-1 and PD-L1 blockade and focus on the reported clinical studies that have included patients with melanoma.

Methods: PubMed was searched to identify relevant clinical studies of PD-1/PD-L1-targeted therapies in melanoma. A review of data from the current trials on was incorporated, as well as data presented in abstracts at the 2014 annual meeting of the American Society of Clinical Oncology, given the limited number of published clinical trials on this topic.

Findings: The anti-PD-1 and anti-PD-L1 agents have been reported to have impressive antitumor effects in several malignancies, including melanoma. The greatest clinical activity in unselected patients has been seen in melanoma. Tumor expression of PD-L1 is a suggestive, but inadequate, biomarker predictive of response to immune-checkpoint blockade. However, tumors expressing little or no PD-L1 are less likely to respond to PD-1 pathway blockade. Combination checkpoint blockade with PD-1 plus cytotoxic T-lymphocyte antigen (CTLA)-4 blockade appears to improve response rates in patients who are less likely to respond to single-checkpoint blockade. Toxicity with PD-1 blocking agents is less than the toxicity with previous immunotherapies (eg, interleukin 2, CTLA-4 blockade). Certain adverse events can be severe and potentially life threatening, but most can be prevented or reversed with close monitoring and appropriate management.

Implications: This family of immune-checkpoint inhibitors benefits not only patients with metastatic melanoma but also those with historically less responsive tumor types. Although a subset of patients responds to single-agent blockade, the initial trial of checkpoint-inhibitor combinations has reported a potential to improve response rates. Combination therapies appear to be a means of increasing response rates, albeit with increased immune-related adverse events. As these treatments become available to patients, education regarding the recognition and management of immune-related effects of immune-checkpoint blockade will be essential for maximizing clinical benefit.

Keywords: MPDL3280A; PD-1; PD-L1; melanoma; nivolumab; pembrolizumab; pidilizumab; programmed cell death 1.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, +19 authors, F Stephen Hodi.
Nature, 2014 Nov 28; 515(7528). PMID: 25428504    Free PMC article.
Highly Cited.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison.
Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101    Free PMC article.
Highly Cited.
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
S A Rosenberg, J C Yang, +6 authors, D E White.
JAMA, 1994 Mar 23; 271(12). PMID: 8120958
Highly Cited.
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Michael R Green, Stefano Monti, +9 authors, Margaret A Shipp.
Blood, 2010 Jul 16; 116(17). PMID: 20628145    Free PMC article.
Highly Cited.
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Y Ishida, Y Agata, K Shibahara, T Honjo.
EMBO J, 1992 Nov 01; 11(11). PMID: 1396582    Free PMC article.
Highly Cited.
Prognostic and predictive markers for the new immunotherapies.
Kathleen M Mahoney, Michael B Atkins.
Oncology (Williston Park), 2014 Nov 12; 28 Suppl 3. PMID: 25384886
The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response.
Hassnae Afrache, Philippe Gouret, +2 authors, Daniel Olive.
Immunogenetics, 2012 Sep 25; 64(11). PMID: 23000944
Overall survival and PD-L1 expression in metastasized malignant melanoma.
Jules Gadiot, Anna I Hooijkaas, +3 authors, Christian Blank.
Cancer, 2011 Apr 28; 117(10). PMID: 21523733
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.
Arlene H Sharpe, E John Wherry, Rafi Ahmed, Gordon J Freeman.
Nat Immunol, 2007 Feb 17; 8(3). PMID: 17304234
Highly Cited. Review.
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
R Houston Thompson, Susan M Kuntz, +11 authors, Eugene D Kwon.
Cancer Res, 2006 Apr 06; 66(7). PMID: 16585157
Highly Cited.
Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.
R Khattri, J A Auger, +2 authors, J A Bluestone.
J Immunol, 1999 May 07; 162(10). PMID: 10229811
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Julie R Brahmer, Charles G Drake, +17 authors, Suzanne L Topalian.
J Clin Oncol, 2010 Jun 03; 28(19). PMID: 20516446    Free PMC article.
Highly Cited.
PD-1 inhibits antiviral immunity at the effector phase in the liver.
Yoshiko Iwai, Seigo Terawaki, +2 authors, Tasuku Honjo.
J Exp Med, 2003 Jul 09; 198(1). PMID: 12847136    Free PMC article.
Highly Cited.
Immune Checkpoint Blockade in Cancer Therapy.
Michael A Postow, Margaret K Callahan, Jedd D Wolchok.
J Clin Oncol, 2015 Jan 22; 33(17). PMID: 25605845    Free PMC article.
Highly Cited. Review.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Jedd D Wolchok, Axel Hoos, +9 authors, F Stephen Hodi.
Clin Cancer Res, 2009 Nov 26; 15(23). PMID: 19934295
Highly Cited.
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Manish J Butte, Mary E Keir, +2 authors, Gordon J Freeman.
Immunity, 2007 Jul 17; 27(1). PMID: 17629517    Free PMC article.
Highly Cited.
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
Christopher J Nirschl, Charles G Drake.
Clin Cancer Res, 2013 Jul 23; 19(18). PMID: 23868869    Free PMC article.
Highly Cited. Review.
Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis.
T T Chang, C Jabs, +2 authors, A H Sharpe.
J Exp Med, 1999 Sep 08; 190(5). PMID: 10477557    Free PMC article.
Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice.
Shimpei Kasagi, Seiji Kawano, +7 authors, Shunichi Kumagai.
J Immunol, 2010 Feb 09; 184(5). PMID: 20139271
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.
Hironori Ueda, Joanna M M Howson, +50 authors, Stephen C L Gough.
Nature, 2003 May 02; 423(6939). PMID: 12724780
Highly Cited.
Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues.
Tetsuya Honda, Jackson G Egen, +3 authors, Ronald N Germain.
Immunity, 2014 Jan 21; 40(2). PMID: 24440150    Free PMC article.
Highly Cited.
Viral immune evasion due to persistence of activated T cells without effector function.
A J Zajac, J N Blattman, +4 authors, R Ahmed.
J Exp Med, 1998 Dec 22; 188(12). PMID: 9858507    Free PMC article.
Highly Cited.
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.
Richard V Parry, Jens M Chemnitz, +6 authors, James L Riley.
Mol Cell Biol, 2005 Oct 18; 25(21). PMID: 16227604    Free PMC article.
Highly Cited.
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Dirk Schadendorf, F Stephen Hodi, +7 authors, Jedd D Wolchok.
J Clin Oncol, 2015 Feb 11; 33(17). PMID: 25667295    Free PMC article.
Highly Cited.
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
Philippe Armand, Arnon Nagler, +21 authors, Leo I Gordon.
J Clin Oncol, 2013 Oct 16; 31(33). PMID: 24127452    Free PMC article.
Highly Cited.
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
R Houston Thompson, Michael D Gillett, +12 authors, Eugene D Kwon.
Proc Natl Acad Sci U S A, 2004 Dec 01; 101(49). PMID: 15569934    Free PMC article.
Highly Cited.
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Marco Gerlinger, Andrew J Rowan, +28 authors, Charles Swanton.
N Engl J Med, 2012 Mar 09; 366(10). PMID: 22397650    Free PMC article.
Highly Cited.
Hepatotoxicity with combination of vemurafenib and ipilimumab.
Antoni Ribas, F Stephen Hodi, +2 authors, Jedd Wolchok.
N Engl J Med, 2013 Apr 05; 368(14). PMID: 23550685
Highly Cited.
Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis.
Bing Wan, Hong Nie, +6 authors, Jingwu Z Zhang.
J Immunol, 2006 Dec 05; 177(12). PMID: 17142787
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.
Raanan Berger, Rinat Rotem-Yehudar, +6 authors, Arnon Nagler.
Clin Cancer Res, 2008 May 17; 14(10). PMID: 18483370
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Alternative splice variants of the human PD-1 gene.
Christian Nielsen, Line Ohm-Laursen, +2 authors, Søren T Lillevang.
Cell Immunol, 2005 Sep 21; 235(2). PMID: 16171790
Differential binding properties of B7-H1 and B7-DC to programmed death-1.
Pornpan Youngnak, Yuko Kozono, +8 authors, Miyuki Azuma.
Biochem Biophys Res Commun, 2003 Aug 02; 307(3). PMID: 12893276
Regulation of surface and intracellular expression of CTLA4 on mouse T cells.
M L Alegre, P J Noel, +4 authors, C B Thompson.
J Immunol, 1996 Dec 01; 157(11). PMID: 8943377
Highly Cited.
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, +23 authors, Antoni Ribas.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724846    Free PMC article.
Highly Cited.
Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, +25 authors, Paolo A Ascierto.
N Engl J Med, 2014 Nov 18; 372(4). PMID: 25399552
Highly Cited.
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H Nishimura, M Nose, +2 authors, T Honjo.
Immunity, 1999 Sep 15; 11(2). PMID: 10485649
Highly Cited.
Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Julia A Brown, David M Dorfman, +5 authors, Gordon J Freeman.
J Immunol, 2003 Jan 23; 170(3). PMID: 12538684
Highly Cited.
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.
Chuan-Yong Mu, Jian-An Huang, +2 authors, Xue-Guang Zhang.
Med Oncol, 2010 Apr 08; 28(3). PMID: 20373055
Highly Cited.
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis.
Bernd H Zinselmeyer, Sara Heydari, +7 authors, Dorian B McGavern.
J Exp Med, 2013 Mar 27; 210(4). PMID: 23530125    Free PMC article.
Highly Cited.
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Y Latchman, C R Wood, +18 authors, G J Freeman.
Nat Immunol, 2001 Feb 27; 2(3). PMID: 11224527
Highly Cited.
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice.
Taku Okazaki, Yoshimasa Tanaka, +8 authors, Tasuku Honjo.
Nat Med, 2003 Nov 05; 9(12). PMID: 14595408
Highly Cited.
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression.
Chunxiao Xu, Christine M Fillmore, +21 authors, Kwok-Kin Wong.
Cancer Cell, 2014 May 06; 25(5). PMID: 24794706    Free PMC article.
Highly Cited.
The B7 family revisited.
Rebecca J Greenwald, Gordon J Freeman, Arlene H Sharpe.
Annu Rev Immunol, 2005 Mar 18; 23. PMID: 15771580
Highly Cited. Review.
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
G J Freeman, A J Long, +16 authors, T Honjo.
J Exp Med, 2000 Oct 04; 192(7). PMID: 11015443    Free PMC article.
Highly Cited.
Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.
Lancet, 1999 Feb 19; 353(9146). PMID: 10023944
Highly Cited.
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.
Cheryl L Day, Daniel E Kaufmann, +19 authors, Bruce D Walker.
Nature, 2006 Aug 22; 443(7109). PMID: 16921384
Highly Cited.
Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages.
Philip Smith, Caitriona M Walsh, +4 authors, Padraic G Fallon.
J Immunol, 2004 Jul 09; 173(2). PMID: 15240716
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Suzanne L Topalian, Mario Sznol, +18 authors, F Stephen Hodi.
J Clin Oncol, 2014 Mar 05; 32(10). PMID: 24590637    Free PMC article.
Highly Cited.
PD-1 and its ligands in tolerance and immunity.
Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe.
Annu Rev Immunol, 2008 Jan 05; 26. PMID: 18173375
Highly Cited. Review.
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.
Jason R Westin, Fuliang Chu, +19 authors, Sattva S Neelapu.
Lancet Oncol, 2013 Dec 18; 15(1). PMID: 24332512    Free PMC article.
Highly Cited.
Activation-induced expression of human programmed death-1 gene in T-lymphocytes.
R Vibhakar, G Juan, +2 authors, L R Finger.
Exp Cell Res, 1997 Apr 10; 232(1). PMID: 9141617
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
Jeffrey S Weber, Ragini Reiney Kudchadkar, +11 authors, Y Ann Chen.
J Clin Oncol, 2013 Oct 23; 31(34). PMID: 24145345    Free PMC article.
Highly Cited.
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
Thomas Powles, Joseph Paul Eder, +12 authors, Nicholas J Vogelzang.
Nature, 2014 Nov 28; 515(7528). PMID: 25428503
Highly Cited.
CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.
P A van der Merwe, D L Bodian, +2 authors, S J Davis.
J Exp Med, 1997 Feb 03; 185(3). PMID: 9053440    Free PMC article.
Highly Cited.
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.
Ryosuke Hino, Kenji Kabashima, +5 authors, Yoshiki Tokura.
Cancer, 2010 Feb 10; 116(7). PMID: 20143437
Highly Cited.
Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program.
Roxanne Payne, Lyn Glenn, +6 authors, Brendan D Curti.
J Immunother Cancer, 2014 May 24; 2. PMID: 24855563    Free PMC article.
In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
Changyu Wang, Kent B Thudium, +15 authors, Alan J Korman.
Cancer Immunol Res, 2014 May 30; 2(9). PMID: 24872026
Highly Cited.
Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes.
Jian Wang, Taku Yoshida, +3 authors, Tasuku Honjo.
Proc Natl Acad Sci U S A, 2005 Aug 10; 102(33). PMID: 16087865    Free PMC article.
Highly Cited.
Structures of PD-1 with its ligands: sideways and dancing cheek to cheek.
Gordon J Freeman.
Proc Natl Acad Sci U S A, 2008 Jul 25; 105(30). PMID: 18650389    Free PMC article.
PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis.
Spencer C Liang, Rebecca J Greenwald, +4 authors, Arlene H Sharpe.
Eur J Immunol, 2005 Dec 17; 36(1). PMID: 16358363
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
Janis M Taube, Alison Klein, +7 authors, Robert A Anders.
Clin Cancer Res, 2014 Apr 10; 20(19). PMID: 24714771    Free PMC article.
Highly Cited.
B7-H1 (CD274) inhibits the development of herpetic stromal keratitis (HSK).
Her Jun, Su K Seo, +4 authors, In-Hak Choi.
FEBS Lett, 2005 Oct 29; 579(27). PMID: 16253242
Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2.
Richard W Joseph, Jeanette E Eckel-Passow, +9 authors, Ryan J Sullivan.
J Immunother, 2012 Oct 24; 35(9). PMID: 23090080
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.
Yoshiko Iwai, Seigo Terawaki, Tasuku Honjo.
Int Immunol, 2004 Dec 22; 17(2). PMID: 15611321
Highly Cited.
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
Janis M Taube, Robert A Anders, +8 authors, Lieping Chen.
Sci Transl Med, 2012 Mar 31; 4(127). PMID: 22461641    Free PMC article.
Highly Cited.
A new therapeutic strategy for malaria: targeting T cell exhaustion.
Gordon J Freeman, Arlene H Sharpe.
Nat Immunol, 2012 Jan 21; 13(2). PMID: 22261959    Free PMC article.
Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis.
Nancy Rodig, Timothy Ryan, +8 authors, Gordon J Freeman.
Eur J Immunol, 2003 Oct 28; 33(11). PMID: 14579280
Highly Cited.
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Yoshiko Iwai, Masayoshi Ishida, +3 authors, Nagahiro Minato.
Proc Natl Acad Sci U S A, 2002 Sep 10; 99(19). PMID: 12218188    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Daniel Sanghoon Shin, Antoni Ribas.
Curr Opin Immunol, 2015 Jan 27; 33. PMID: 25621841
Highly Cited. Review.
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.
Igor Puzanov, Ravi K Amaravadi, +10 authors, Kevin B Kim.
Eur J Cancer, 2015 May 20; 51(11). PMID: 25980594    Free PMC article.
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.
Alexander Faje.
Pituitary, 2015 Jul 19; 19(1). PMID: 26186958
Highly Cited. Review.
The potential of tumor-derived exosomes for noninvasive cancer monitoring.
Theresa L Whiteside.
Expert Rev Mol Diagn, 2015 Aug 21; 15(10). PMID: 26289602    Free PMC article.
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets.
Giuseppe Palmieri, MariaNeve Ombra, +6 authors, Antonio Cossu.
Front Oncol, 2015 Sep 01; 5. PMID: 26322273    Free PMC article.
The Evolution of Therapies in Non-Small Cell Lung Cancer.
Vishal Boolell, Muhammad Alamgeer, David N Watkins, Vinod Ganju.
Cancers (Basel), 2015 Sep 16; 7(3). PMID: 26371045    Free PMC article.
Clinical implications of basic research in hepatocellular carcinoma.
Renumathy Dhanasekaran, Sudhakar K Venkatesh, Michael S Torbenson, Lewis R Roberts.
J Hepatol, 2015 Oct 10; 64(3). PMID: 26450813    Free PMC article.
Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy.
Vinod Vijay Subhash, Mei Shi Yeo, Woei Loon Tan, Wei Peng Yong.
J Immunol Res, 2015 Nov 19; 2015. PMID: 26579545    Free PMC article.
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.
Krzysztof M Zak, Radoslaw Kitel, +6 authors, Tad A Holak.
Structure, 2015 Nov 26; 23(12). PMID: 26602187    Free PMC article.
Highly Cited.
Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.
Juanita Lopez, Sam Harris, Desam Roda, Timothy A Yap.
Transl Oncogenomics, 2015 Nov 27; 7(Suppl 1). PMID: 26609214    Free PMC article.
PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells.
Andrea L George, Robert Suriano, +7 authors, Raj K Tiwari.
J Cancer, 2015 Dec 08; 6(12). PMID: 26640592    Free PMC article.
Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies.
Noura Choudhury, Yusuke Nakamura.
Cancer Sci, 2015 Dec 19; 107(2). PMID: 26678880    Free PMC article.
Immune Checkpoint Blockade in Hepatocellular Carcinoma.
M Kudo.
Liver Cancer, 2016 Jan 07; 4(4). PMID: 26732472    Free PMC article.
SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells.
Shira Ashkenazi, Rona Ortenberg, +2 authors, Gal Markel.
Oncotarget, 2016 Feb 18; 7(21). PMID: 26885752    Free PMC article.
Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis.
Ran Chen, Pei-Chun Peng, +8 authors, Xin Deng.
Transl Oncol, 2016 Mar 08; 9(1). PMID: 26947879    Free PMC article.
The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines.
Xiuwen Guan, Haijuan Wang, +3 authors, Binghe Xu.
Medicine (Baltimore), 2016 Mar 18; 95(11). PMID: 26986169    Free PMC article.
Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Subrata Chowdhury, Joe Veyhl, +5 authors, Paul G Walfish.
Oncotarget, 2016 Apr 19; 7(22). PMID: 27086918    Free PMC article.
Pembrolizumab in classical Hodgkin's lymphoma.
Joseph Maly, Lapo Alinari.
Eur J Haematol, 2016 May 06; 97(3). PMID: 27147112    Free PMC article.
A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses.
Italia Grenga, Renee N Donahue, +2 authors, Jeffrey Schlom.
Clin Transl Immunology, 2016 Jun 29; 5(5). PMID: 27350882    Free PMC article.
A Perspective of Immunotherapy for Prostate Cancer.
Ida Silvestri, Susanna Cattarino, +3 authors, Alessandro Sciarra.
Cancers (Basel), 2016 Jul 12; 8(7). PMID: 27399780    Free PMC article.
Keratoacanthoma-appearing melanoma metastases in a patient receiving pembrolizumab therapy.
Heather Schopper, Nicholas M Bontumasi, Mohammed Milhem, Karolyn A Wanat.
JAAD Case Rep, 2016 Jul 14; 2(3). PMID: 27408934    Free PMC article.
Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.
Xue Li, Minghuan Li, +4 authors, Jinming Yu.
Target Oncol, 2016 Jul 17; 11(6). PMID: 27422273
Systematic Review.
Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer.
Robert Gibson, Jess Delaune, Anita Szady, Merry Markham.
BMJ Case Rep, 2016 Jul 22; 2016. PMID: 27440853    Free PMC article.
Development of a Modular Assay for Detailed Immunophenotyping of Peripheral Human Whole Blood Samples by Multicolor Flow Cytometry.
Paul F Rühle, Rainer Fietkau, Udo S Gaipl, Benjamin Frey.
Int J Mol Sci, 2016 Aug 17; 17(8). PMID: 27529227    Free PMC article.
Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model.
Ana M Contreras-Sandoval, María Merino, +3 authors, María J Garrido.
Oncotarget, 2016 Oct 21; 7(47). PMID: 27764774    Free PMC article.
PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab.
Ali R Jazirehi, Alexandra Lim, Tam Dinh.
Am J Cancer Res, 2016 Nov 09; 6(10). PMID: 27822406    Free PMC article.
Basis for molecular diagnostics and immunotherapy for esophageal cancer.
Joe Abdo, Devendra K Agrawal, Sumeet K Mittal.
Expert Rev Anticancer Ther, 2016 Nov 15; 17(1). PMID: 27838937    Free PMC article.
Filling the Tank: Keeping Antitumor T Cells Metabolically Fit for the Long Haul.
Greg M Delgoffe.
Cancer Immunol Res, 2016 Dec 03; 4(12). PMID: 27908931    Free PMC article.
Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
Aaron T Mayer, Arutselvan Natarajan, +5 authors, Sanjiv S Gambhir.
J Nucl Med, 2016 Dec 17; 58(4). PMID: 27980047    Free PMC article.
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update.
M Kudo.
Liver Cancer, 2016 Dec 21; 6(1). PMID: 27995082    Free PMC article.
PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.
Joseph M Obeid, Gulsun Erdag, +5 authors, Craig L Slingluff.
Oncoimmunology, 2016 Dec 22; 5(11). PMID: 27999753    Free PMC article.
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Xinqi Wu, Anita Giobbie-Hurder, +15 authors, F Stephen Hodi.
Cancer Immunol Res, 2016 Dec 23; 5(1). PMID: 28003187    Free PMC article.
Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination.
Lakshmi Jayashankar, Richard Hafner.
Front Immunol, 2016 Dec 27; 7. PMID: 28018344    Free PMC article.
Novel implications in the treatment of hepatocellular carcinoma.
Jan Best, Clemens Schotten, +7 authors, Guido Gerken.
Ann Gastroenterol, 2017 Jan 04; 30(1). PMID: 28042235    Free PMC article.
A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.
Drew C Deniger, Mei Li M Kwong, +5 authors, Steven A Rosenberg.
Clin Cancer Res, 2017 Jan 18; 23(2). PMID: 28093487    Free PMC article.
Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.
C Alberti.
G Chir, 2017 Jan 18; 37(5). PMID: 28098061    Free PMC article.
A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.
Z J Wolner, A A Marghoob, +2 authors, M A Marchetti.
Br J Dermatol, 2017 Jan 31; 178(1). PMID: 28132411    Free PMC article.
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.
M Higgins, G Curigliano, +14 authors, P Goss.
Breast Cancer Res Treat, 2017 Feb 09; 162(3). PMID: 28176175    Free PMC article.
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer.
Ruea-Yea Huang, Ariel Francois, +2 authors, Kunle Odunsi.
Oncoimmunology, 2017 Feb 16; 6(1). PMID: 28197366    Free PMC article.
Highly Cited.
Immune-Mediated Therapies for Liver Cancer.
Rajagopal N Aravalli, Clifford J Steer.
Genes (Basel), 2017 Feb 22; 8(2). PMID: 28218682    Free PMC article.
Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model.
Shintaro Ishikawa, Takako Ishikawa, +3 authors, Tadashi Hisamitsu.
Evid Based Complement Alternat Med, 2017 Mar 14; 2017. PMID: 28286532    Free PMC article.
Immunotherapy in pancreatic cancer treatment: a new frontier.
Komal Thind, Leslie J Padrnos, Ramesh K Ramanathan, Mitesh J Borad.
Therap Adv Gastroenterol, 2017 Mar 14; 10(1). PMID: 28286568    Free PMC article.
Acute Hyperglycemia Associated with Anti-Cancer Medication.
Yul Hwangbo, Eun Kyung Lee.
Endocrinol Metab (Seoul), 2017 Mar 28; 32(1). PMID: 28345313    Free PMC article.
Molecular genetic and immunotherapeutic targets in metastatic melanoma.
C Melis, A Rogiers, O Bechter, Joost J van den Oord.
Virchows Arch, 2017 Mar 31; 471(2). PMID: 28357489
Cancer immunotherapy: how low-level ionizing radiation can play a key role.
Marek K Janiak, Marta Wincenciak, +2 authors, Edward J Calabrese.
Cancer Immunol Immunother, 2017 Apr 01; 66(7). PMID: 28361232    Free PMC article.
The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.
Xia Fang, Bing Xiu, +10 authors, Yu Zeng.
Medicine (Baltimore), 2017 Apr 14; 96(15). PMID: 28403071    Free PMC article.
Second Primary Cancer Risk among Kidney Cancer Patients in Korea: A Population-Based Cohort Study.
Jae Young Joung, Whi-An Kwon, +8 authors, Young-Joo Won.
Cancer Res Treat, 2017 Apr 20; 50(1). PMID: 28421722    Free PMC article.
Focus on cutaneous and uveal melanoma specificities.
Charlotte Pandiani, Guillaume E Béranger, +2 authors, Corine Bertolotto.
Genes Dev, 2017 May 18; 31(8). PMID: 28512236    Free PMC article.
A Case Report of Drug-Induced Myopathy Involving Extraocular Muscles after Combination Therapy with Tremelimumab and Durvalumab for Non-Small Cell Lung Cancer.
William Carrera, Brandon J Baartman, Gregory Kosmorsky.
Neuroophthalmology, 2017 May 18; 41(3). PMID: 28512504    Free PMC article.
Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.
David A Bond, Lapo Alinari.
J Blood Med, 2017 May 27; 8. PMID: 28546779    Free PMC article.
Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma.
Simon Bossart, Selina Thurneysen, +7 authors, Reinhard Dummer.
Oncologist, 2017 Jun 01; 22(6). PMID: 28559410    Free PMC article.
Anti-Bovine Programmed Death-1 Rat-Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle.
Tomohiro Okagawa, Satoru Konnai, +10 authors, Kazuhiko Ohashi.
Front Immunol, 2017 Jun 24; 8. PMID: 28638381    Free PMC article.
Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy.
Jose D Sandoval-Sus, Francis Mogollon-Duffo, +4 authors, Michael V Jagal.
J Immunother Cancer, 2017 Jun 24; 5. PMID: 28642818    Free PMC article.
Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Chunyan Hao, Jinhui Tian, +3 authors, Bingdong Zhu.
Medicine (Baltimore), 2017 Jun 29; 96(26). PMID: 28658143    Free PMC article.
Systematic Review.
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.
Cesare Gridelli, Andrea Ardizzoni, +5 authors, Filippo De Marinis.
Transl Lung Cancer Res, 2017 Jul 18; 6(3). PMID: 28713682    Free PMC article.
Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Lea Bottlaender, Anne-Laure Breton, +3 authors, Stephane Dalle.
J Immunother Cancer, 2017 Jul 19; 5(1). PMID: 28716106    Free PMC article.
Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer.
Jing Sun, Hong Tao, +5 authors, Yundi Guo.
Oncol Lett, 2017 Aug 10; 14(2). PMID: 28789456    Free PMC article.
Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer.
Kazuhiko Takaya, Miwa Sonoda, Ayako Fuchigami, Toru Hiyoshi.
Intern Med, 2017 Aug 22; 56(18). PMID: 28824067    Free PMC article.
Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
Johan Falkenius, Hemming Johansson, +3 authors, Suzanne Egyhazi Brage.
BMC Cancer, 2017 Aug 31; 17(1). PMID: 28851300    Free PMC article.
Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.
Ping-Pin Zheng, Jin Li, Johan M Kros.
Med Res Rev, 2017 Sep 02; 38(1). PMID: 28862319    Free PMC article.
Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide.
David A Davis, Suraj Mishra, +8 authors, Robert Yarchoan.
Oncotarget, 2017 Sep 09; 8(31). PMID: 28881567    Free PMC article.
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.
Jinfeng Cao, Niels J Brouwer, +6 authors, Martine J Jager.
Oncotarget, 2017 Sep 15; 8(33). PMID: 28903377    Free PMC article.
Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy.
Gerlig Widmann, Van Anh Nguyen, Julian Plaickner, Werner Jaschke.
Curr Radiol Rep, 2016 Jan 01; 5(11). PMID: 28959504    Free PMC article.
Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth.
Gijung Kwak, Dongkyu Kim, +5 authors, Yoon Yeo.
ACS Nano, 2017 Oct 07; 11(10). PMID: 28985469    Free PMC article.
Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine.
Toshiro Shirakawa, Koichi Kitagawa.
Hum Vaccin Immunother, 2017 Oct 20; 14(1). PMID: 29048978    Free PMC article.
Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors.
Charles Caldwell, Cory E Johnson, +3 authors, Raghuraman Kannan.
Sci Rep, 2017 Oct 24; 7(1). PMID: 29057919    Free PMC article.
Intratumor and Intertumor Heterogeneity in Melanoma.
Tomasz M Grzywa, Wiktor Paskal, Paweł K Włodarski.
Transl Oncol, 2017 Oct 28; 10(6). PMID: 29078205    Free PMC article.
Highly Cited. Review.
Cardiotoxicity of immune checkpoint inhibitors.
Gilda Varricchi, Maria Rosaria Galdiero, +5 authors, Carlo Gabriele Tocchetti.
ESMO Open, 2017 Nov 07; 2(4). PMID: 29104763    Free PMC article.
Highly Cited. Review.
Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection.
Mi Jung Kwon, Kab-Choong Kim, +8 authors, Kyueng-Whan Min.
Oncotarget, 2017 Nov 16; 8(47). PMID: 29137273    Free PMC article.
IL-21 Therapy Controls Immune Activation and Maintains Antiviral CD8+ T Cell Responses in Acute Simian Immunodeficiency Virus Infection.
Gema Méndez-Lagares, Ding Lu, +5 authors, Dennis J Hartigan-O'Connor.
AIDS Res Hum Retroviruses, 2017 Nov 16; 33(S1). PMID: 29140110    Free PMC article.
Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.
Sébastien A Felt, Valery Z Grdzelishvili.
J Gen Virol, 2017 Nov 17; 98(12). PMID: 29143726    Free PMC article.
Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature.
Jean-Jacques Grob, Laurent Mortier, +11 authors, Frédéric F Lehmann.
ESMO Open, 2017 Nov 28; 2(5). PMID: 29177094    Free PMC article.
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.
Xinxin Zhu, Jinghe Lang.
Oncotarget, 2017 Dec 13; 8(57). PMID: 29228642    Free PMC article.
Highly Cited. Review.
Case report on the role of radiofrequency-assisted spleen-preserving surgery for splenic metastasis in the era of check-point inhibitors.
Satwinder Mudan, Jayant Kumar, +5 authors, Nagy Habib.
Medicine (Baltimore), 2017 Dec 17; 96(49). PMID: 29245341    Free PMC article.
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
Susanne M Steggerda, Mark K Bennett, +18 authors, Matthew I Gross.
J Immunother Cancer, 2017 Dec 20; 5(1). PMID: 29254508    Free PMC article.
Highly Cited.
Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.
Zhengping Hu, Liang Ye, +2 authors, Tao Xi.
Sci Rep, 2018 Jan 11; 8(1). PMID: 29317734    Free PMC article.
Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.
Davis A Witt, Andrew M Donson, +9 authors, Andrea M Griesinger.
Pediatr Blood Cancer, 2018 Jan 20; 65(5). PMID: 29350470    Free PMC article.
Skin microbiota-host interactions.
Y Erin Chen, Michael A Fischbach, Yasmine Belkaid.
Nature, 2018 Jan 25; 553(7689). PMID: 29364286    Free PMC article.
Highly Cited. Review.
PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Priya Srinivasan, Xiaofang Wu, +2 authors, Anthony D Sandler.
PLoS Med, 2018 Jan 30; 15(1). PMID: 29377881    Free PMC article.
Refractory thyroid carcinoma: which systemic treatment to use?
Laurence Faugeras, Anne-Sophie Pirson, +4 authors, Lionel D'Hondt.
Ther Adv Med Oncol, 2018 Feb 06; 10. PMID: 29399055    Free PMC article.
The Potential Role of circRNA in Tumor Immunity Regulation and Immunotherapy.
Zihao Xu, Peiyao Li, Li Fan, Minghua Wu.
Front Immunol, 2018 Feb 07; 9. PMID: 29403493    Free PMC article.
Highly Cited. Review.
Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases.
Surabhi Ranjan, Martha Quezado, +9 authors, Jing Wu.
BMC Cancer, 2018 Mar 02; 18(1). PMID: 29490632    Free PMC article.
In vitro immunotherapy potency assays using real-time cell analysis.
Fabio Cerignoli, Yama A Abassi, +6 authors, Biao Xi.
PLoS One, 2018 Mar 03; 13(3). PMID: 29499048    Free PMC article.
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.
Emily Z Keung, Esosa U Ukponmwan, Alexandria P Cogdill, Jennifer A Wargo.
Ann Surg Oncol, 2018 Mar 04; 25(7). PMID: 29500764    Free PMC article.
Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines.
Morgan Grau, Paul R Walker, Madiha Derouazi.
Cell Mol Life Sci, 2018 Mar 07; 75(16). PMID: 29508006    Free PMC article.
Checks and Balances in Autoimmune Vasculitis.
Rebeca Hid Cadena, Wayel H Abdulahad, +4 authors, Elisabeth Brouwer.
Front Immunol, 2018 Mar 10; 9. PMID: 29520282    Free PMC article.
Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy.
Soumaya Kouidhi, Farhat Ben Ayed, Amel Benammar Elgaaied.
Front Immunol, 2018 Mar 13; 9. PMID: 29527212    Free PMC article.
Highly Cited. Review.
Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.
Mei Zhang, Julian A Kim, Alex Yee-Chen Huang.
Front Immunol, 2018 Mar 15; 9. PMID: 29535722    Free PMC article.
Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.
Polina Shindiapina, Lapo Alinari.
Ther Adv Hematol, 2018 Apr 07; 9(4). PMID: 29623180    Free PMC article.
CD8+ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy.
Jillian Rosenberg, Jun Huang.
Curr Opin Chem Eng, 2018 Apr 07; 19. PMID: 29623254    Free PMC article.
Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers.
Joe Abdo, David L Cornell, Sumeet K Mittal, Devendra K Agrawal.
Front Oncol, 2018 Apr 13; 8. PMID: 29644213    Free PMC article.
Combined inhibition of JAK1,2/Stat3‑PD‑L1 signaling pathway suppresses the immune escape of castration‑resistant prostate cancer to NK cells in hypoxia.
Li-Jun Xu, Qi Ma, +8 authors, Yu-Xi Shan.
Mol Med Rep, 2018 Apr 26; 17(6). PMID: 29693186    Free PMC article.
T Cell Calcium Signaling Regulation by the Co-Receptor CD5.
Claudia M Tellez Freitas, Deborah K Johnson, K Scott Weber.
Int J Mol Sci, 2018 Apr 28; 19(5). PMID: 29701673    Free PMC article.
Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.
Tao Shi, Yanyu Ma, +4 authors, Tingting Wang.
Int J Mol Sci, 2018 May 08; 19(5). PMID: 29735917    Free PMC article.
Activating and inhibitory receptors expressed on innate lymphoid cells.
Sophie Guia, Aurore Fenis, Eric Vivier, Emilie Narni-Mancinelli.
Semin Immunopathol, 2018 May 24; 40(4). PMID: 29789862
Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.
Frantz Dupuis, Laurence Lamant, +10 authors, Béatrice Vergier.
Br J Cancer, 2018 Jul 06; 119(2). PMID: 29973670    Free PMC article.
Microbial biomarkers for immune checkpoint blockade therapy against cancer.
Keishi Adachi, Koji Tamada.
J Gastroenterol, 2018 Jul 14; 53(9). PMID: 30003334    Free PMC article.
Lily extracts inhibit the proliferation of gastric carcinoma SGC-7901 cells by affecting cell cycle progression and apoptosis via the upregulation of caspase-3 and Fas proteins, and the downregulation of FasL protein.
Aihong Wang, Mingquan Wang, +4 authors, Yufeng Zhao.
Oncol Lett, 2018 Jul 17; 16(2). PMID: 30008816    Free PMC article.
Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression.
Barbara Castella, Myriam Foglietta, Chiara Riganti, Massimo Massaia.
Front Immunol, 2018 Jul 18; 9. PMID: 30013559    Free PMC article.
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.
Mark R Albertini, Richard K Yang, +16 authors, Paul M Sondel.
Cancer Immunol Immunother, 2018 Aug 04; 67(10). PMID: 30073390    Free PMC article.
Targeting the Microenvironment in High Grade Serous Ovarian Cancer.
Nkechiyere G Nwani, Livia E Sima, Wilberto Nieves-Neira, Daniela Matei.
Cancers (Basel), 2018 Aug 15; 10(8). PMID: 30103384    Free PMC article.
Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin.
Kavindra Nath, Jeffrey Roman, +10 authors, Jerry D Glickson.
Sci Rep, 2018 Oct 04; 8(1). PMID: 30279592    Free PMC article.
Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma.
Chaoqi Zhang, Zhen Zhang, +11 authors, Yi Zhang.
Oncoimmunology, 2018 Nov 01; 7(11). PMID: 30377558    Free PMC article.
Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression.
Elena Gianchecchi, Alessandra Fierabracci.
Front Immunol, 2018 Nov 06; 9. PMID: 30386337    Free PMC article.
Highly Cited. Review.
PD-L1 expression levels on tumor cells affect their immunosuppressive activity.
Yang Zheng, You-Chen Fang, Jing Li.
Oncol Lett, 2019 Oct 16; 18(5). PMID: 31612048    Free PMC article.
Label-free and specific detection of soluble programmed death ligand-1 using a localized surface plasmon resonance biosensor based on excessively tilted fiber gratings.
Binbin Luo, Yajie Wang, +6 authors, Mingfu Zhao.
Biomed Opt Express, 2019 Oct 28; 10(10). PMID: 31646036    Free PMC article.
Dual Inhibitors-Loaded Nanotherapeutics that Target Kinase Signaling Pathways Synergize with Immune Checkpoint Inhibitor.
Anujan Ramesh, Siva Kumar Natarajan, Dipika Nandi, Ashish Kulkarni.
Cell Mol Bioeng, 2019 Nov 14; 12(5). PMID: 31719920    Free PMC article.
Mass Cytometry Imaging for the Study of Human Diseases-Applications and Data Analysis Strategies.
Heeva Baharlou, Nicolas P Canete, +2 authors, Ellis Patrick.
Front Immunol, 2019 Dec 05; 10. PMID: 31798587    Free PMC article.
Oligosaccharyltransferase: A Gatekeeper of Health and Tumor Progression.
Yoichiro Harada, Yuki Ohkawa, Yasuhiko Kizuka, Naoyuki Taniguchi.
Int J Mol Sci, 2019 Dec 08; 20(23). PMID: 31810196    Free PMC article.
CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors.
Ruchi Saxena, Yan Wang, James W Mier.
Melanoma Res, 2019 Sep 17; 30(1). PMID: 31524789    Free PMC article.
Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy.
Francesco Perri, Franco Ionna, +5 authors, Francesco Caponigro.
Transl Oncol, 2019 Dec 24; 13(2). PMID: 31869751    Free PMC article.
TLR3 regulates PD-L1 expression in human cytomegalovirus infected glioblastoma.
Ziying Qin, Li Zhang, +8 authors, Bin Wang.
Int J Clin Exp Pathol, 2018 Nov 01; 11(11). PMID: 31949612    Free PMC article.
A novel chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products.
Keke Li, Shuang Zhao, +7 authors, Cong Peng.
Cancer Cell Int, 2020 Feb 06; 20. PMID: 32021565    Free PMC article.
Therapeutic host-directed strategies to improve outcome in tuberculosis.
C Young, G Walzl, N Du Plessis.
Mucosal Immunol, 2019 Nov 28; 13(2). PMID: 31772320    Free PMC article.
NLRC5: new cancer buster?
Feng Tang, Yadi Xu, Bing Zhao.
Mol Biol Rep, 2020 Jan 12; 47(3). PMID: 31925644
Adolescent and young adult patients with cancer: a milieu of unique features.
Leonard Sender, Keri B Zabokrtsky.
Nat Rev Clin Oncol, 2015 May 27; 12(8). PMID: 26011488
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.
Tessa Knox, Eva Sahakian, +14 authors, Alejandro Villagra.
Sci Rep, 2019 Apr 18; 9(1). PMID: 30992475    Free PMC article.
Highly Cited.
Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract.
Kiichiro Teruya, Yoshihiro Kusumoto, +2 authors, Sanetaka Shirahata.
Mar Drugs, 2019 Jul 25; 17(7). PMID: 31331053    Free PMC article.
Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy.
Alexandr V Bazhin, Amedeo Amedei, Svetlana Karakhanova.
Front Immunol, 2018 Dec 21; 9. PMID: 30568661    Free PMC article.
Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer.
Lukas W Pfannenstiel, C Marcela Diaz-Montero, +3 authors, Brian R Gastman.
Cancer Immunol Res, 2019 Feb 08; 7(3). PMID: 30728151    Free PMC article.
Divergent SATB1 expression across human life span and tissue compartments.
Simone Nüssing, Hui-Fern Koay, +12 authors, Katherine Kedzierska.
Immunol Cell Biol, 2019 Feb 26; 97(5). PMID: 30803026    Free PMC article.
An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids.
Nobuhiko Takahashi, Hirotaka Hoshi, +11 authors, Motoki Takagi.
Cells, 2019 May 30; 8(5). PMID: 31137590    Free PMC article.
PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.
Zhengping Hu, Pengfei Yu, +7 authors, Jingwei Tian.
PLoS One, 2020 Mar 28; 15(3). PMID: 32214351    Free PMC article.
Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.
Francesca Romana Mariotti, Linda Quatrini, +2 authors, Lorenzo Moretta.
Front Immunol, 2019 May 21; 10. PMID: 31105707    Free PMC article.
Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology.
Gaurav Bajaj, Satyendra Suryawanshi, Amit Roy, Manish Gupta.
Br J Clin Pharmacol, 2019 May 30; 85(9). PMID: 31140642    Free PMC article.
Pembrolizumab for the Treatment of Hepatocellular Carcinoma.
Masatoshi Kudo.
Liver Cancer, 2019 Jun 14; 8(3). PMID: 31192152    Free PMC article.
Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
Wanfeng Gao, Xiaoyun Zhang, +12 authors, Tao Sun.
J Immunother Cancer, 2019 Aug 30; 7(1). PMID: 31462297    Free PMC article.
Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab.
N Shah, J Jacob, +3 authors, H Soudy.
J Immunother Cancer, 2019 Sep 13; 7(1). PMID: 31511075    Free PMC article.
Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies.
Masatoshi Kudo.
Liver Cancer, 2020 Jun 02; 8(6). PMID: 32479569    Free PMC article.
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Jayesh Desai, Sanjeev Deva, +22 authors, Michael Millward.
J Immunother Cancer, 2020 Jun 17; 8(1). PMID: 32540858    Free PMC article.
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
Lin Shen, Jun Guo, +18 authors, Yi-Long Wu.
J Immunother Cancer, 2020 Jun 21; 8(1). PMID: 32561638    Free PMC article.
The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis.
Jingjie Chen, Shengnan Li, +8 authors, Yingying Tang.
World J Surg Oncol, 2020 Jul 06; 18(1). PMID: 32620130    Free PMC article.
Systematic Review.
Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.
Massimo Ralli, Andrea Botticelli, +6 authors, Antonio Greco.
J Immunol Res, 2020 Jul 17; 2020. PMID: 32671117    Free PMC article.
Large-Scale Analysis Reveals the Specific Clinical and Immune Features of DGCR5 in Glioma.
Xuechao Wu, Peng Hou, +2 authors, Xiaojie Lu.
Onco Targets Ther, 2020 Aug 18; 13. PMID: 32801772    Free PMC article.
Gated Resonance Energy Transfer (gRET) Controlled by Programmed Death Protein Ligand 1.
Hubert Grel, Katarzyna Ratajczak, Slawomir Jakiela, Magdalena Stobiecka.
Nanomaterials (Basel), 2020 Aug 23; 10(8). PMID: 32823551    Free PMC article.
The detailed distribution of T cell subpopulations in immune-stable renal allograft recipients: a single center study.
Quan Zhuang, Bo Peng, +5 authors, Yingzi Ming.
PeerJ, 2019 Feb 19; 7. PMID: 30775184    Free PMC article.
MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers.
Ibrahim Halil Erdogdu.
Gastroenterol Res Pract, 2019 Mar 19; 2019. PMID: 30881447    Free PMC article.
Therapeutic targeting of immune checkpoints with small molecule inhibitors.
Wade M Smith, Ian J Purvis, +7 authors, Swapna Asuthkar.
Am J Transl Res, 2019 Mar 23; 11(2). PMID: 30899360    Free PMC article.
Boron-incorporating hemagglutinating virus of Japan envelope (HVJ-E) nanomaterial in boron neutron capture therapy.
Shuichiro Yoneoka, Yasuhiro Nakagawa, +3 authors, Mitsuhiro Ebara.
Sci Technol Adv Mater, 2019 Apr 09; 20(1). PMID: 30956733    Free PMC article.
Extracellular Vesicle-Based Therapeutic Targeting of β-Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer.
Akiko Matsuda, Kaori Ishiguro, Irene K Yan, Tushar Patel.
Hepatol Commun, 2019 Apr 13; 3(4). PMID: 30976743    Free PMC article.
Managing cardiotoxicity associated with immune checkpoint inhibitors.
Sireesha Upadhrasta, Hadi Elias, Keval Patel, Lei Zheng.
Chronic Dis Transl Med, 2019 Apr 18; 5(1). PMID: 30993259    Free PMC article.
Pembrolizumab for cutaneous squamous cell carcinoma: Report of a case of inoperable squamous cell carcinoma with complete response to pembrolizumab complicated by granulomatous inflammation.
Mireille L M van Baar, Alex D Guminski, Peter M Ferguson, Linda K Martin.
JAAD Case Rep, 2019 Jun 14; 5(6). PMID: 31193588    Free PMC article.
Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients.
Sumi Yun, Yujun Park, +6 authors, Kyu Sang Lee.
J Cancer, 2019 Jul 10; 10(13). PMID: 31281485    Free PMC article.
Emerging strategies to treat rare and intractable subtypes of melanoma.
Gretchen M Alicea, Vito W Rebecca.
Pigment Cell Melanoma Res, 2020 Apr 11; 34(1). PMID: 32274887    Free PMC article.
Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer.
Junyoung Choi, Hee Jin Lee, +15 authors, Dae Ho Lee.
Am J Cancer Res, 2020 Oct 13; 10(9). PMID: 33042623    Free PMC article.
Modeling Immune Checkpoint Inhibitor Efficacy in Syngeneic Mouse Tumors in an Ex Vivo Immuno-Oncology Dynamic Environment.
Daniel T Doty, Julia Schueler, +4 authors, Jeffrey T Borenstein.
Int J Mol Sci, 2020 Sep 10; 21(18). PMID: 32899865    Free PMC article.
Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
Liangliang Meng, Xiaoxi He, +6 authors, Yueyong Xiao.
PLoS One, 2020 Oct 09; 15(10). PMID: 33031392    Free PMC article.
Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome.
Gil Bar-Sela, Idan Cohen, +10 authors, David Meiri.
Cancers (Basel), 2020 Sep 03; 12(9). PMID: 32872248    Free PMC article.
The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
Fiona A Desland, Adília Hormigo.
Int J Mol Sci, 2020 Oct 09; 21(19). PMID: 33027976    Free PMC article.
Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies.
Kaijian Zhou, Shu Guo, +2 authors, Guoxin Liang.
Front Cell Dev Biol, 2020 Nov 13; 8. PMID: 33178688    Free PMC article.
Update on uveal melanoma: Translational research from biology to clinical practice (Review).
Miguel A Ortega, Oscar Fraile-Martínez, +4 authors, Miguel A Teus.
Int J Oncol, 2020 Nov 12; 57(6). PMID: 33173970    Free PMC article.
Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma.
Alexander P Landry, Michael Balas, +2 authors, Zsolt Zador.
Sci Rep, 2020 Nov 13; 10(1). PMID: 33177572    Free PMC article.
Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses.
Adarsh Kumbhari, Colt A Egelston, Peter P Lee, Peter S Kim.
Front Immunol, 2020 Nov 17; 11. PMID: 33193401    Free PMC article.
Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.
Yong Qin, Kathryn Bollin, +14 authors, Sapna P Patel.
J Immunother Cancer, 2020 Nov 19; 8(2). PMID: 33203661    Free PMC article.
PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
Lulu Rong, Yong Liu, +12 authors, Ning Lu.
Diagn Pathol, 2019 Jan 28; 14(1). PMID: 30684971    Free PMC article.
Antitumor activity of ginsenoside Rg3 in melanoma through downregulation of the ERK and Akt pathways.
Lingbin Meng, Rui Ji, +3 authors, Xin Jiang.
Int J Oncol, 2019 May 14; 54(6). PMID: 31081060    Free PMC article.
Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab.
Anna Kathrin Stüven, Bertram Wiedenmann.
Oncotarget, 2019 May 31; 10(35). PMID: 31143376    Free PMC article.
Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes.
Javier Arranz-Nicolás, Miguel Martin-Salgado, +6 authors, Isabel Merida.
J Immunother Cancer, 2020 Nov 29; 8(2). PMID: 33246984    Free PMC article.
Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis.
Qi Zhang, Geng-Wei Huo, Hong-Zhen Zhang, Ying Song.
Open Med (Wars), 2020 Dec 15; 15(1). PMID: 33313405    Free PMC article.
A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability.
Judith Lacey, Anna J Lomax, +5 authors, Haryana M Dhillon.
Support Care Cancer, 2018 Nov 06; 27(4). PMID: 30392112
Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma.
Dingwei Ye, Jiyan Liu, +17 authors, Feng Bi.
Cancer Sci, 2020 Oct 14; 112(1). PMID: 33047430    Free PMC article.
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer.
Dhruv Bansal, Melissa A Reimers, Eric M Knoche, Russell K Pachynski.
Cancers (Basel), 2021 Jan 23; 13(2). PMID: 33477569    Free PMC article.
NECTIN4: A Novel Therapeutic Target for Melanoma.
Yuka Tanaka, Maho Murata, +2 authors, Takamichi Ito.
Int J Mol Sci, 2021 Jan 23; 22(2). PMID: 33478111    Free PMC article.
Biomimetic Anti-PD-1 Peptide-Loaded 2D FePSe3 Nanosheets for Efficient Photothermal and Enhanced Immune Therapy with Multimodal MR/PA/Thermal Imaging.
Xueyang Fang, Xianlin Wu, +5 authors, Wing-Tak Wong.
Adv Sci (Weinh), 2021 Jan 30; 8(2). PMID: 33511018    Free PMC article.
Nanobodies targeting immune checkpoint molecules for tumor immunotherapy and immunoimaging (Review).
Sheng Yu, Gui Xiong, +7 authors, Siliang Duan.
Int J Mol Med, 2021 Jan 09; 47(2). PMID: 33416134    Free PMC article.
A combinational chemo-immune therapy using an enzyme-sensitive nanoplatform for dual-drug delivery to specific sites by cascade targeting.
Yanmei He, Lei Lei, +9 authors, Nicholas A Peppas.
Sci Adv, 2021 Feb 07; 7(6). PMID: 33547067    Free PMC article.
Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy.
Saskia Bolz, Thivyah Ramakrishnan, +9 authors, Tim Hagenacker.
eNeurologicalSci, 2021 Feb 20; 22. PMID: 33604462    Free PMC article.
PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme.
Jakub Litak, Wiesława Grajkowska, +4 authors, Cezary Grochowski.
Brain Sci, 2021 Mar 07; 11(2). PMID: 33669639    Free PMC article.
Beyond immune checkpoint blockade: emerging immunological strategies.
Shawn P Kubli, Thorsten Berger, +2 authors, Tak W Mak.
Nat Rev Drug Discov, 2021 Mar 10; 20(12). PMID: 33686237
Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.
Rangarirai Makuku, Neda Khalili, +2 authors, Nima Rezaei.
J Immunol Res, 2021 Mar 09; 2021. PMID: 33681388    Free PMC article.
Nucleic Acid Immunotherapeutics for Cancer.
Tingting Shen, Yu Zhang, +3 authors, Guizhi Zhu.
ACS Appl Bio Mater, 2021 Mar 09; 3(5). PMID: 33681722    Free PMC article.
Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma.
Xubin Dong, Jingjing Song, +7 authors, Haiguang Liu.
Front Oncol, 2021 Mar 16; 10. PMID: 33718105    Free PMC article.
The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses.
Guanglin Cui.
Front Oncol, 2021 Mar 26; 11. PMID: 33763344    Free PMC article.
Distinct genomic features across cytolytic subgroups in skin melanoma.
Constantinos Roufas, Ilias Georgakopoulos-Soares, Apostolos Zaravinos.
Cancer Immunol Immunother, 2021 Mar 30; 70(11). PMID: 33779796    Free PMC article.
Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer.
Pilar Martín, Rafael Blanco-Domínguez, Raquel Sánchez-Díaz.
Cell Mol Immunol, 2020 Nov 26; 18(4). PMID: 33235388    Free PMC article.
Molecular Characteristics of Genes and the Immune Microenvironment of a Rare Chest Malignant Tumor (Pulmonary Clear Cell Sarcoma): A Case Report.
Xiaoling Xu, Ding Wang, Wei Wu, Hongyang Lu.
Front Oncol, 2021 Apr 09; 11. PMID: 33828995    Free PMC article.
CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement.
Chao Li, Eleanor Brant, Hikmet Budak, Baohong Zhang.
J Zhejiang Univ Sci B, 2021 Apr 10; 22(4). PMID: 33835761    Free PMC article.
SAMD9 Is Relating With M2 Macrophage and Remarkable Malignancy Characters in Low-Grade Glioma.
Wenping Ma, Kenan Zhang, +2 authors, Ying Zhang.
Front Immunol, 2021 May 04; 12. PMID: 33936093    Free PMC article.
Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.
Rituparna Chakrabarti, Bhavya Kapse, Gayatri Mukherjee.
Cancer Rep (Hoboken), 2020 Jul 29; 2(4). PMID: 32721130    Free PMC article.
Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1.
Weimin Chen, Madhu Pandey, +7 authors, Shihua Lin.
MAbs, 2021 Apr 20; 13(1). PMID: 33870864    Free PMC article.
Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study.
Julie Valentin, Thomas Ferté, +6 authors, Emilie Gérard.
J Oncol, 2021 May 18; 2021. PMID: 33995528    Free PMC article.
Age-Associated Changes in Adverse Events Arising From Anti-PD-(L)1 Therapy.
Xinyi Huang, Tiantian Tian, +3 authors, Jiandong Zhang.
Front Oncol, 2021 Jun 01; 11. PMID: 34055598    Free PMC article.
Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer.
Ryusuke Murakami, Junzo Hamanishi, +9 authors, Masaki Mandai.
Sci Rep, 2021 Jun 03; 11(1). PMID: 34075161    Free PMC article.
PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects.
Enrico Munari, Francesca R Mariotti, +9 authors, Lorenzo Moretta.
Int J Mol Sci, 2021 Jun 03; 22(10). PMID: 34066087    Free PMC article.
FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.
Steve Y Cho, Daniel T Huff, Robert Jeraj, Mark R Albertini.
Semin Nucl Med, 2020 Oct 17; 50(6). PMID: 33059821    Free PMC article.
PD-1 Coexpression Gene Analysis and the Regulatory Network in Endometrial Cancer Based on Bioinformatics Analysis.
Lina Wang, Zhen Liu, +2 authors, Pengpeng Qu.
Biomed Res Int, 2021 Jun 15; 2021. PMID: 34124265    Free PMC article.
Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.
Portia L Thomas, Sarah M Groves, +16 authors, Christine M Lovly.
J Thorac Oncol, 2021 Apr 12; 16(7). PMID: 33839362    Free PMC article.
PD-1 Inhibitors Could Improve the Efficacy of Chemotherapy as First-Line Treatment in Biliary Tract Cancers: A Propensity Score Matching Based Analysis.
Miaomiao Gou, Yong Zhang, +5 authors, Guanghai Dai.
Front Oncol, 2021 Jul 06; 11. PMID: 34221968    Free PMC article.
Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners.
Marek Z Wojtukiewicz, Magdalena M Rek, +7 authors, Kenneth V Honn.
Cancer Metastasis Rev, 2021 Jul 09; 40(3). PMID: 34236546    Free PMC article.
Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas.
Kazuhiko Hashimoto, Shunji Nishimura, Tomohiko Ito, Masao Akagi.
Eur J Histochem, 2021 Jul 06; 65(3). PMID: 34218652    Free PMC article.
Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors.
Jonathan W Riess, Shaila Rahman, +20 authors, Siraj M Ali.
Transl Oncol, 2021 Aug 02; 14(10). PMID: 34333275    Free PMC article.
Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition.
Brittany B Campbell, Melissa A Galati, +26 authors, Uri Tabori.
Cancer Discov, 2021 Feb 11; 11(6). PMID: 33563663    Free PMC article.
Activation of interferon regulatory factor 3 by replication-competent vaccinia viruses improves antitumor efficacy mediated by T cell responses.
Stephanie Riederer, Robert Fux, +3 authors, Juan J Rojas.
Mol Ther Oncolytics, 2021 Sep 24; 22. PMID: 34553028    Free PMC article.
N -Methyladenosine and Rheumatoid Arthritis: A Comprehensive Review.
Sha Wu, Xiao-Feng Li, +3 authors, Jun Li.
Front Immunol, 2021 Oct 12; 12. PMID: 34630412    Free PMC article.
Pembrolizumab-associated autoimmune haemolytic anaemia.
Philippa Johnstone, Omar Khan.
BMJ Case Rep, 2019 Oct 28; 12(10). PMID: 31653618    Free PMC article.
Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer.
Tao Feng, Jiahui Zhao, +8 authors, Yong Luo.
Front Immunol, 2021 Oct 30; 12. PMID: 34712244    Free PMC article.
A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy.
Qiong Xiang, Shuai Dong, Xian-Hui Li.
Med Sci Monit, 2021 Oct 10; 27. PMID: 34625526    Free PMC article.
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond.
Orla Fitzpatrick, Jarushka Naidoo.
Lung Cancer (Auckl), 2021 Nov 11; 12. PMID: 34754256    Free PMC article.
CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion.
Ming Wang, Jiaoying Jia, +2 authors, Yugang Jiang.
Cell Death Dis, 2021 Nov 11; 12(11). PMID: 34753903    Free PMC article.
T cell receptor (TCR) signaling in health and disease.
Kinjal Shah, Amr Al-Haidari, Jianmin Sun, Julhash U Kazi.
Signal Transduct Target Ther, 2021 Dec 14; 6(1). PMID: 34897277    Free PMC article.
Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report.
Dong Won Baek, Yee Soo Chae.
Yeungnam Univ J Med, 2021 Mar 23; 38(4). PMID: 33752275    Free PMC article.
In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction.
Chih-Hao Lu, Wei-Min Chung, +3 authors, Huey-En Tzeng.
Sci Rep, 2022 Jan 09; 12(1). PMID: 34996924    Free PMC article.
Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases.
Vishakha Singh, Amit Khurana, +3 authors, Ralf Weiskirchen.
Front Pharmacol, 2022 Jan 11; 12. PMID: 35002724    Free PMC article.
Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.
Kavindra Nath, David S Nelson, +4 authors, Jerry D Glickson.
Anticancer Res, 2017 Jul 03; 37(7). PMID: 28668829    Free PMC article.
A Darwinian perspective on tumor immune evasion.
Julieann Puleo, Kornelia Polyak.
Biochim Biophys Acta Rev Cancer, 2021 Dec 22; 1877(1). PMID: 34933050    Free PMC article.
Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.
M Villagrán-García, R Velasco.
Neurol Sci, 2022 Feb 18; 43(4). PMID: 35175441
Lirilumab and Avelumab Enhance Anti-HPV+ Cervical Cancer Activity of Natural Killer Cells via Vav1-Dependent NF-κB Disinhibition.
Hongli Liu, Sihui Zhou, +7 authors, Nan Wu.
Front Oncol, 2022 Feb 18; 12. PMID: 35174079    Free PMC article.
Ferroptosis-related gene SLC1A5 is a novel prognostic biomarker and correlates with immune infiltrates in stomach adenocarcinoma.
Dandan Zhu, Sifan Wu, +6 authors, Tieying Hou.
Cancer Cell Int, 2022 Mar 21; 22(1). PMID: 35305616    Free PMC article.
Case Report: Complete Remission With Anti-PD-1 and Anti-VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma.
Weiran Xu, Kai Wang, +5 authors, Jun Liang.
Front Oncol, 2022 Mar 22; 12. PMID: 35311098    Free PMC article.
In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy.
Jiehan Li, Guang Luo, +8 authors, Yingjie Zhang.
Mater Today Bio, 2022 Mar 26; 14. PMID: 35330634    Free PMC article.
Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions.
Fernando López-Campos, Pablo Gajate, +5 authors, Felipe Couñago.
Biomedicines, 2022 Mar 26; 10(3). PMID: 35327339    Free PMC article.
Exploring the Role of Transglutaminase in Patients with Glioblastoma: Current Perspectives.
William P Katt, Cody Aplin, Richard A Cerione.
Onco Targets Ther, 2022 Mar 29; 15. PMID: 35340676    Free PMC article.
Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas.
Yifan Zhang, Yi Chen, +3 authors, Felix Haglund.
Biomolecules, 2022 Feb 26; 12(2). PMID: 35204793    Free PMC article.
A Pan-Cancer Bioinformatic Analysis of RAD51 Regarding the Values for Diagnosis, Prognosis, and Therapeutic Prediction.
Hengrui Liu, Jieling Weng.
Front Oncol, 2022 Apr 02; 12. PMID: 35359409    Free PMC article.
Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers.
J Tabernero, F Andre, +7 authors, I Melero.
ESMO Open, 2022 Mar 20; 7(2). PMID: 35305400    Free PMC article.
The role of cell-penetrating peptides in potential anti-cancer therapy.
Meiling Zhou, Xi Zou, +7 authors, Yiqun Jiang.
Clin Transl Med, 2022 May 21; 12(5). PMID: 35593206    Free PMC article.